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Metformin is a widely prescribed medication that has been used to treat children with type
2 diabetes in the United States for the past 15 years. Metformin now has a variety of clinical
applications in pediatrics, and its potential clinical uses continue to expand. In addition to
reviewing the current understanding of its mechanisms of action including the newly discov-
ered effects on the gastrointestinal tract, we will also discuss current clinical uses in pediatrics,
including in type 1 diabetes. Finally, we examine the existing state of monitoring for metformin
efficacy and side effects and discuss prospective future clinical uses.
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1 | INTRODUCTION
Metformin is an ancient herbal remedy derived from the French lilac
that appears in herbal guides dating from the 17th century and
described to have properties suitable for treating the symptoms of
what we now know to be diabetes.1 The specific compound metfor-
min (dimethyl biguanide) was first synthesized in 1922. However, its
use was eclipsed by the production of synthetic insulin around the
same time.2 In the 1950’s, the French scientist Jean Sterne published
on metformin’s properties and named the compound Glucophage,
which means glucose eater. From then on, it has been used for the
treatment of diabetes. Metformin has found favor for its mild side
effect profile, affordability, ease of administration, and positive
effects on body weight. Metformin is an oral medication with
extended release preparations that allows for once daily dosing. The
primary concern is the risk for lactic acidosis in certain patient popu-
lations, although this has been estimated to occur at a rate of
9:100 000 patient years.3,4 Metformin was approved for use in the
United States in 1994. Following the improvement in morbidity and
mortality in type 2 diabetes demonstrated in the United Kingdom
Prospective Diabetes Study (UKPDS), metformin has been recom-
mended as the first line oral treatment for type 2 diabetes by the
American Diabetes Association (ADA) and the European Association
for the Study of Diabetes (EASD) since 2009.5,6 It is estimated that
there are close to 50 million annual prescriptions for metformin in
the United States.7
2 | MECHANISM OF ACTION
Despite the long clinical experience with metformin and active inves-
tigation in this area, its exact mechanisms of action remain unclear. In
fact, there have been 100 indexed publications on this subject per
year since 2008. Metformin is given at large doses relative to other
pharmaceuticals, to achieve a therapeutic effect. The therapeutic
dose for most patients is in the range of 2 grams per day, suggesting
that the effect is not the result of an interaction with a specific pro-
tein target. Metformin requires transporters to enter cells and for
uptake into the kidney where it is excreted unmetabolized. Poly-
morphisms in these transporters have been linked to changes in the
therapeutic metformin effect in certain patients. Large cohort studies
have also indicated polymorphisms in downstream signaling pathways
as other mediators of metformin effect.8,9
Metformin concentrates in the hepatic circulation. Recent studies
have suggested that metformin may have a direct effect on the gas-
trointestinal mucosa, and the jejeunal concentrations in humans can
be up to 300 times that detected in the plasma.2 Indeed, gastrointes-
tinal side effects are common but may also be an indicator of thera-
peutic efficacy. Many of the studies on the mechanism of action of
metformin have been performed with concentrations of the drug in
in vitro culture that are now thought to be supratherapeutic. How-
ever, the concentration that cells are exposed to is tissue dependent
with the liver and gastrointestinal tract facing much higher levels of
the drug.
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3 | LIVER
Early studies of the mechanisms of action of metformin used cultured
hepatocytes. From these studies metformin was shown to have a
specific but mild inhibitory effect on complex 1 of the mitochondrial
respiratory chain.10 This is thought to change the cellular energy state
triggering AMP activated protein kinase (AMPK), a nutrient sensor
activated in states of low energy balance. However, some actions of
metformin have been found to be AMPK-independent.11 Metformin
treatment also has beneficial indirect effects that result from lowering
circulating glucose and insulin levels.
Metformin was shown to have its predominant effect on lower-
ing blood glucose by decreasing hepatic glucose production in iso-
lated hepatocytes. Later human studies showed a decrease in fasting
plasma glucose and gluconeogenesis in patients taking metformin.12
Patients with type 2 diabetes have increased hepatic glucose output
at baseline, which is then decreased by 75% in metformin users.13
Recent studies have found that metformin decreases hepatic gluco-
neogenesis via antagonism of the glucagon signaling pathway and
also by inhibition of gluconeogenic enzymes in the mitochondria.14,15
However, the effects may only be seen at relatively high medication
doses. The impact of metformin treatment on circulating glucagon
levels in patients with type 2 diabetes is still a matter of debate.
4 | PERIPHERAL INSULIN SENSITIVE
TISSUES
Early animal experiments demonstrated enhanced muscle and liver
glucose uptake after dosing with metformin.16 In human studies,
chronic metformin treatment was shown in hyperinsulinemic euglyce-
mic clamps to increase peripheral glucose uptake.17 In in vitro rodent
studies it was found to increase insulin-dependent glucose transport
into the cell as well as the insulin receptor number and insulin recep-
tor activity.16,18,19 It is thought that these actions in the muscle again
only occurred at high metformin doses.
5 | GASTROINTESTINAL TRACT
Metformin’s effect on the intestine has also begun to be explored in
more detail, as this is a major site of drug concentration. Metformin is
thought to play a role in decreasing intestinal glucose uptake.20 In
addition, metformin has been demonstrated to have an effect on the
composition of the intestinal microbiome, which may contribute to its
weight lowering effect. In a recent human study by Forslund et al.,
the specific effect of metformin independent of hyperglycemia was
evaluated. In this study the microbiome of patients from 3 cohorts
were studied (total n = 784) and the metformin-specific effect
included an increase in Escherichia species that was proportional to
blood metformin level.21 In addition, the microbial community analy-
sis in the metformin-treated patients with type 2 diabetes more
closely resembled the control group than the type 2 diabetes group,
possibly indicating a rescue from dysbiosis associated with type
2 diabetes.
Incretin hormones from the gut also play a major role in glucose
homeostasis. Metformin has been shown to increase postprandial
glucagon-like peptide-1 (GLP-1) levels. Metformin has also been
shown to increase GLP-1 receptor expression.22 It is also thought the
increased GLP-1 half-life occurs through a mild decrease in the activ-
ity of the degrading enzyme dipeptidyl peptidase 4 (DPP-4); however
this mild effect is not likely to make a large contribution to overall cir-
culating active GLP-1 levels.23 Finally, metformin treatment has been
associated with an increase in gut Escherichia species, and E.coli has
been shown to have a direct association with GLP-1 levels.22
Much remains to be discovered about the specific mechanism of
action of metformin. Understanding these molecular mechanisms
may then lead to the design of more specific compounds to achieve
metabolic effects while decreasing the possibility of off target effects.
A summary of the sites of action of metformin discussed in this
review appear in Figure 1.
6 | CLINICAL USES IN PEDIATRICS
6.1 | Type 2 diabetes
Metformin is widely utilized for treatment of type 2 diabetes due to
its ability to reduce insulin levels and improve glycemic control. Met-
formin has been shown to decrease hemoglobin A1c values by 1.3%-
2%, and the degree of reduction is higher in patients with higher pre-
treatment blood glucose levels.19 In a small trial in adolescents, this
decrease was 0.7%.24 In the UKPDS, the metformin group had
improved cardiovascular morbidity and mortality. In addition, the
metformin group had better overall health outcomes independent of
the degree of lowering of A1c, suggesting additional beneficial effects
of metformin. These results lead to the adoption of metformin as the
primary agent in both adult and pediatric type 2 diabetes. In terms of
patients at risk for type 2 diabetes, the Diabetes Prevention Program
(DPP) revealed that lifestyle intervention was as or more effective
than using metformin to prevent type 2 diabetes.25,26 Metformin did
however reduce progression to type 2 diabetes. Metformin is FDA
approved for use in patients greater than 10 years of age and the
extended release preparation in patients over 17.27
6.2 | Type 1 diabetes
Recent interest has been generated in using metformin in type 1 dia-
betes to improve diabetic control as well as manage weight gain in
overweight teens. In a pilot study metformin use in type 1 diabetes
led to a decrease in insulin dose and improvements in BMI and waist
circumference in female participants.28 This led to the larger rando-
mized clinical trial conducted by Libman et al. In this study, although
metformin appeared to have an effect on decreasing insulin doses
and weight gain at 26 weeks, the HbA1c of the adolescents on met-
formin was not significantly changed. The authors concluded that
addition of metfomrin was not beneficial since the teens also had
increased complaints of gastrointestinal distress.29 Metformin has
shown some potential in preclinical studies to improve diabetic
nephropathy, decrease advanced glycation end products (AGE), which
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mediate some diabetic complications, and decrease oxidative stress in
endothelial cells. In addition, it has been shown in human clinical
studies to improve outcomes in patients with heart failure regardless
of lowering of hemoglobin A1c.30 Finally, it has shown some benefit
in lowering androgen levels in females with type 1 diabetes and
hyperandrogenism.31 For these reasons, metformin remains a poten-
tial treatment in type 1 diabetes and may prove beneficial in longer
term studies or specific patient populations.
6.3 | Obesity
Metformin has been explored for potential weight loss properties and
was shown in a meta-analysis to lead to a mild weight loss of
1.1 kg.32 In a separate meta-analysis of trials of overweight and
obese adolescents, a combination of metformin and lifestyle changes
decreased the body mass index (BMI) by 1.42 as well as the fasting
insulin and homeostatic model assessment (HOMA).33 Only 1 of the
included studies followed the participants for 2 years after the treat-
ment in an attempt to detect a legacy effect and found that the
favorable effects on weight subsided after 24 weeks.34 Indeed fol-
lowing the DPP there was a smaller study showing 10 year post
study outcome. In this study, the metformin group showed continued
improvement in weight from initial study baseline; however this
effect seems to be driven by participants age 45 and older at ran-
domization.35 Metformin has also been shown to be mildly beneficial
in weight reduction when added to regimens that include medications
that cause weight gain, such as antipsychotic medications.36 The
inclusion of metformin along with an antipsychotic also had additional
benefits as it decreased prolactin levels, which increase with antipsy-
chotic treatment and result in side effects such as menstrual irregula-
rities and galactorrhea.37 In studies of children with type 2 diabetes
metformin often in combination with lifestyle intervention decreased
weight by up to 2.7 kg.24 In addition, metformin can supplement
exercise to improve left ventricular systolic function in those with
insulin resistance.38 Metformin has also can been shown to be associ-
ated with a mild decrease n circulating triglyceride levels and LDL
cholesterol levels. However in the treatment options for type 2 diabe-
tes in adolescents and youth (TODAY) study these effects were not
seen in the metformin alone group.39
There was also a recent publication examining the impact of met-
formin on linear growth in children. This was a meta-analysis of
10 studies in children with a total of over 500 participants. They
found that metformin was associated with a small increase in height
on the order of 1 cm in the subgroup that had high dose metformin
treatment.40 This effect seems driven in large part by a single study
using metformin in girls who were had low birthweight and early
onset of puberty. The treatment in this group began on average at
age 9. Future studies of metformin use in children should include
detailed height measurements to better understand this potential
effect.
Liver:
•  Decreases gluconeogenesis
•  Antagonizes glucagon signaling
•  Inhibitis Complex 1 of the
   mitochondrial respiratory chain
•  Improves fasting plasma glucose
Muscle:
•  Increases glucose uptake
•  Increases glucose transporters
•  Increases insulin receptor
   number and activity
•  Improves inuslin sensitivity
Adipose:
•  Decreases inflammation and
   adipose tissue
•  Reduces fibrosis in white
   adipose tissue
•  Improves inuslin sensitivity
Ovary:
•  Decreases theca cell
   production of
   androstenedione
•  Decreases androgen producing
   enzyme activity in granulosa
   cells
•  May restore ovulation in
   females with PCOS
GI tract:
•  Decreases intestinal glucose upake
•  Increased mucin production
•  Alters the microbiome
•  Increases GLP-1 secretion
•  Improves postprandial blood glucose
FIGURE 1 A summary of the main sites of metformin action along with the clinical impact on each organ system (underlined).
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Finally, a small study was conducted to determine if metformin
could prevent adiposity in prepubertal children who were born small
for gestational age and had rapid catch up growth. This group of chil-
dren is typically at increased risk for metabolic diseases in adult-
hood.41 In this study metformin administration at a low dose (425 mg
daily) for 24 months improved abdominal fat as measured by MRI, tri-
glycerides, and insulin resistance as measured by HOMA-IR.42
6.4 | Polycystic ovary syndrome
Metformin is also used in the treatment of polycystic ovary syndrome
(PCOS). It has been shown to have a direct effect on the ovary lead-
ing to a decrease in theca cell androstenedione production. It also
decreases FSH-stimulated androgen producing enzyme activity in the
granulosa cells (3betaHSD, StAR, CYP11a1, and aromatase). Of note,
premature pubarche/adrenarche and eventually PCOS are often diag-
nosed in the same patient, although it is still unclear if those entities
share a common pathophysiology. In a small study of children with
premature pubarche, treatment with metformin delayed the onset of
puberty by 0.4 years and after 4 years of treatment the girls in the
study had gained 5.5 kg less fat than control subjects.43,44 They also
showed an improvement in androgen levels, insulin resistance and
lipids, and these effects persisted 1 year after the treatment was dis-
continued.45 Thus the potential for metformin as a preventative
agent in girls at risk of PCOS may exist.
6.5 | Non-alcoholic fatty liver disease
Metformin has an effect on lipid handling in the hepatocyte, and this
has been shown to be via an AMPK-dependent mechanism.20 There-
fore, metformin is being studied for use in non-alcoholic fatty liver
disease (NAFLD) in children. In 1 study there was no benefit of met-
formin vs lifestyle in improvement of fatty liver disease. However,
there was a decrease in the grade of inflammation in the liver upon
biopsy with metformin treatment.46 Another study found no
improvement in NAFLD in metformin vs placebo but they concluded
that the dose may have been too low given that there were also no
changes in insulin sensitivity, which had been seen in the pilot
study.46 A subsequent study examined metformin vs vitamin E sup-
plementation and found that metformin can improve liver disease but
that it is inferior to vitamin E treatment when taken long term. The
major effect occurred at the 2 month point and was not significant at
4 months.47 At this time metformin is not recommended for treat-
ment of NAFLD in children. According to experts in the field, further
studies including biopsy specimens need to be done. In adult meta-
analyses of studies including liver histology there was also no
improvement seen with metformin.
7 | EMERGING USES
Interest in using metformin as a preventative measure, treatment, or
adjuvant drug for cancer has emerged. One study found that in those
with diabetes mellitus and gastrointestinal cancers, metformin coupled
with a statin appeared to be beneficial in upper gastroinstinal cancers,
but not for those with lower gastrointestinal cancers.48 There also did
not seem to be an effect in those with advanced pancreatic cancers,
which led the authors to speculate that it may be a dose-dependent
response, which may be blunted in those with advanced cancers.49 In
terms of the increased risk of cancer in patients with diabetes, it is
possible that metformin may decrease this risk. However it does not
appear to improve survival time in those patients who do have cancer.
Indeed some researchers think the efficacy of metformin as a cancer
therapy depends on the molecular pathways that have been altered in
the tumor cells.50 Additionally, the doses or routes of administration
used for diabetes treatment may not be appropriate for cancer chemo-
therapy. Metformin also decreases the circulating insulin and glucose
levels, and these effects may be beneficial in cancer prevention as
both are mitogenic factors. Metformin also plays a role in activation of
DNA damage repair pathways, which may ultimately protect from the
malignant transformation of cells.50
8 | OTHER INDICATIONS THAT HAVE AN
IMPACT ON CHILDREN
Aside from the pediatric uses described above, infants may also
receive metformin exposure via maternal metformin use during preg-
nancy for indications like PCOS, preexisting type 2 diabetes or gesta-
tional diabetes. In PCOS, the treatment window begins peri-
conceptionally while with gestational diabetes the treatment usually
begins during the second trimester. Studies of metformin use in preg-
nancy began in the 1970’s. While its use remains off-label in preg-
nancy in the United States, metformin is used during pregnancy more
routinely worldwide. A meta-analysis of studies using metformin for
gestational diabetes indicated an improvement in macrosomia, infant
hypoglycemia, pregnancy induced hypertension, and maternal weight
gain.51 There are now trials looking at the use of metformin in obese
non-diabetic pregnant women and also in the postnatal period to pre-
vent the development of type 2 diabetes after gestational diabetes.
Since clinical studies have provided some evidence of a legacy effect
remaining in patients after the withdrawal of the medication, it stands
to reason that metformin could potentially induce lasting epigenetic
changes. Indeed it has been shown to modulate the activity of dicer,
a major component of the microRNA processing machinery.52 Further
studies of offspring of women treated with metformin in pregnancy
need to be conducted. A follow-up study of infants born to mothers
treated with metformin for gestational diabetes published results at
age 2. This showed an increase in subscapular skinfold thickness by
calipers but no changes in body composition by dual energy x-ray
absorptiometry (DXA) in a smaller subset of the children.53 The ongo-
ing study is due to publish results on prepubertal offspring soon.
There are preclinical studies in pediatric populations evaluating
the possibility of metformin as an intervention after neonatal hypoxe-
mic ischemic brain injury. In this model it was shown to increase the
number of neural precursor cells.54 There is also a clinical trial under-
way evaluating the possible use of metformin in combination with
another agent in children with Duchenne muscular dystrophy.55 A
summary of current approved uses and potential future applications
for metformin appears in Table 1
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9 | SIDE EFFECTS AND
CONTRAINDICATIONS
In terms of monitoring during metformin use, there has been a con-
cern about the development of B12 deficiency. This could be consist-
ent with an intestinal site of action of the medication leading to a
low-grade malabsorption. However, in the DPP while lower B12
levels were detected, anemia was not. Monitoring also includes fol-
lowing for changes in liver function. In the pediatric studies of met-
formin there were no reported changes in liver function tests.24
Other concerns surround the contraindications for use of metformin.
The contraindications for use have been renal impairment, surgery,
the use of contrast agents, liver dysfunction, congestive heart failure,
alcoholism, metabolic acidosis, dehydration, and hypoxemia.5 More
recently, however, metformin has shown promise in improving heart
failure and NAFLD. In addition, the renal impairment contraindication
has been debated and laxened, given the very rare occurrence of lac-
tic acidosis that was not proven to have a causal link to metformin in
a Cochrane database review.5,56 A recent case series was published
suggesting a link between metformin use and early onset lung can-
cer.57 Follow-up from this publication will be important since this has
not previously been reported after many patient years of treatment
experience with this medication.
10 | FUTURE PERSPECTIVES
Metformin is considered first line treatment in type 2 diabetes, but
when adequate glycemic control is not achieved, combination therapy
is recommended. Several pharmaceutical manufacturers have
released combination agents for use in type 2 diabetes. In addition to
starting insulin, there are 14 combination pills which include metfor-
min with another oral agent that can be used in individuals greater
than 18 years old. Often these combination agents use other medica-
tions that can also be used independently to treat type 2 diabetes
including Glyburide (sulfonylurea), Canagliflozin (sodium-glucose co-
transporter 2 (SGLT2) inhibitor), and Alogliptin (dipeptidyl peptidase-
4 (DPP-4) inhibitor).58 To date there are no published trials of the use
of these combination agents in the pediatric population.
Newer preparations are also being designed to deposit metfor-
min in different mucosal locations to either enhance current benefi-
cial effects or try to improve efficacy in cancer treatment by
delivering a higher dose but avoiding side effects that typically cause
discontinuation.59 One preparation is made to deliver metformin to
the distal small bowel, as there is a thought that this may be the main
site mediating the effect of the medication. Such localized delivery
would theoretically avoid other systemic sites of action. In addition,
other dosing strategies that allow for direct contact with mucosal sur-
faces being developed include direct bladder lavage after a recent
study showed efficacy in a preclinical model of bladder cancer.60
There is also a clinical trial using a vaginal preparation to treat PCOS
while minimizing size effects in an effort to improve tolerability. A
recent publication also announced a new metformin polymer that can
deliver metformin plus a siRNA species for chemotherapy.
In order for our understanding of the mechanisms of action of
metformin to improve, we must understand the concentrations
achieved in specific target tissues and then be certain to use these
physiologically relevant concentrations in future mechanistic studies.
In addition, many studies also employ an acute exposure timeline,
which may not be relevant to the chronic clinical use of the medica-
tion. Another complicating matter for studies of metformin is that the
effect seems to differ depending on the metabolic and nutrient status
of the recipient. In experimental systems it seems to have an
enhanced effect in states of hyperglycemia and in the setting of high
fat diet. In clinical studies metformin may have beneficial effects on
cardiovascular mortality in only diabetic patients.20 In the DPP parti-
cipants who were younger, weighed more and were women with a
history of gestational diabetes, those individuals had better treatment
efficacy.61
At present the use of measured metformin levels is generally
restricted to determining if cases represent toxicity. Even the thera-
peutic window for metformin effect is not agreed upon. We should
consider routinely measuring metformin levels in clinical studies in
order to understand the correlation between metformin dose and
clinical outcome. Gaining an understanding of the levels achieved in
patients who demonstrate a clinical benefit will allow for more accu-
rate study of metformin actions. A recent clinical study has also
described a potential circulating biomarker of metformin action in
the liver.62 It will be interesting to see how this biomarker contri-
butes to our understanding of metformin activity on an individual
level.
Metformin is a well-tolerated medication that has efficacy in a
variety of clinical conditions and has a low risk of toxicity when
used according to guidelines. However, the effect of metformin
alone is mild in most of the conditions described and often fails
to achieve goal therapeutic endpoints without the addition of
another medication. Additionally, the mechanisms of metformin’s
effects still remain mysterious, leaving the possibility of unfore-
seen consequences, which may now come to attention with wide-
spread use. Despite these drawbacks, metformin is widely used
and its potential clinical applications continue to expand (Table 1).
Indeed, it is now being studied as a treatment to promote longev-
ity suggesting that the future horizons for this ancient compound
are broad.
TABLE 1 Approved and potential uses of metformin in pediatrics
Approved Potential
Type 2 diabetes Type 1 diabetes
Obesity (in conjunction with
lifestyle intervention)
Cancer (solid tumors and leukemia)
PCOS Weight gain with antipsychotic use
Pancreatic beta-cell rest in new
onset type 2 diabetes
Brain injury due to stroke or
radiation therapy
Duchenne muscular dystrophy
Gestational diabetes (fetal
exposure)
Lactation failure (newborn
exposure)
PCOS, polycystic ovary syndrome.
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